Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ensartinib in Resected <i>ALK</i>-Positive Non-Small-Cell Lung Cancer.

The New England journal of medicine·2026
Same author

Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 Study.

Cancer communications (London, England)·2026
Same author

Interaction between Zygosaccharomyces bailii and Schizosaccharomyces pombe enhances acetic acid reduction in Baijiu fermentation.

Food research international (Ottawa, Ont.)·2026
Same author

Ferroptosis and futile recanalization after mechanical thrombectomy in acute ischemic stroke: mechanisms, risk factors, predictive models and therapeutic interventions.

Experimental biology and medicine (Maywood, N.J.)·2026
Same author

Real-World Treatment Patterns and Clinical Outcomes Among Chinese Patients with Stage III NSCLC: The MOOREA Study.

Targeted oncology·2026
Same author

ZNRF2-mediated CD-M6PR degradation and lysosomal dysfunction aggravate cellular senescence and aging.

GeroScience·2026

Related Experiment Video

Updated: Dec 28, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K

Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R

Xi Li1, Li Zhang2, Da Jiang3

  • 1Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|February 16, 2020
PubMed
Summary

High-dose icotinib demonstrated improved progression-free survival and response rates in non-small cell lung cancer (NSCLC) patients with the L858R mutation. This regimen offers a potentially new therapeutic option with acceptable safety.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.5K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K

Related Experiment Videos

Last Updated: Dec 28, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.5K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K

Area of Science:

  • Oncology
  • Pharmacology
  • Medical Research

Background:

  • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality worldwide.
  • Epidermal growth factor receptor (EGFR) mutations, particularly the L858R mutation, are key drivers in a subset of NSCLC patients.
  • Icotinib is an EGFR tyrosine kinase inhibitor used in NSCLC treatment.

Purpose of the Study:

  • To evaluate the safety and efficacy of high-dose icotinib compared to routine-dose icotinib in NSCLC patients with the EGFR L858R mutation.
  • To compare outcomes between different dosing strategies of icotinib and patient subgroups.

Main Methods:

  • A randomized controlled trial involving treatment-naïve NSCLC patients with EGFR mutations (L858R or exon 19 deletion).
  • Patients with L858R mutation were randomized to receive routine-dose (125 mg thrice daily) or high-dose (250 mg thrice daily) icotinib.
  • The primary endpoint was median progression-free survival (mPFS) assessed by an independent review committee.

Main Results:

  • High-dose icotinib (L858R-HD) showed a median progression-free survival (mPFS) of 12.9 months, significantly longer than routine-dose icotinib (L858R-RD) at 9.2 months (HR: 0.75).
  • The objective response rate (ORR) was higher in the high-dose group (73%) compared to the routine-dose group (48%).
  • Incidences of grade 3/4 toxicities were similar across all treatment groups, indicating acceptable tolerability.

Conclusions:

  • High-dose icotinib significantly improved mPFS and ORR in NSCLC patients with the L858R mutation.
  • The high-dose regimen was well-tolerated, suggesting it as a potential new therapeutic option for this patient population.
  • Further research may explore optimal dosing strategies for icotinib in specific NSCLC genetic subtypes.